Free Trial
NASDAQ:GRTS

Gritstone bio (GRTS) Stock Price, News & Analysis

$0.80
0.00 (0.00%)
(As of 05/28/2024 ET)
Today's Range
$0.80
$0.82
50-Day Range
$0.74
$2.81
52-Week Range
$0.67
$3.33
Volume
1.92 million shs
Average Volume
2.70 million shs
Market Capitalization
$86.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75

Gritstone bio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
493.8% Upside
$4.75 Price Target
Short Interest
Healthy
12.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.12mentions of Gritstone bio in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$35,453 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.94) to ($0.87) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.55 out of 5 stars

Medical Sector

690th out of 931 stocks

Biological Products, Except Diagnostic Industry

116th out of 154 stocks

GRTS stock logo

About Gritstone bio Stock (NASDAQ:GRTS)

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

GRTS Stock Price History

GRTS Stock News Headlines

B. Riley Reiterates "Buy" Rating for Gritstone bio (NASDAQ:GRTS)
Beyond The Numbers: 4 Analysts Discuss Gritstone Bio Stock
Nasdaq Down Over 1%; VivoPower International Shares Spike Higher
Why Is Gritstone Bio (GRTS) Stock Down 44% Today?
See More Headlines
Receive GRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
5/28/2024
Next Earnings (Estimated)
8/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:GRTS
Fax
N/A
Employees
231
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.75
High Stock Price Target
$7.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+493.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-138,490,000.00
Net Margins
-926.13%
Pretax Margin
-926.13%

Debt

Sales & Book Value

Annual Sales
$16.34 million
Book Value
$0.54 per share

Miscellaneous

Free Float
103,564,000
Market Cap
$86.86 million
Optionable
Optionable
Beta
0.64
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Andrew R. Allen BCh (Age 58)
    BM, M.D., MA, MRCP, Ph.D., Co-Founder, President, CEO & Director
    Comp: $1.01M
  • Mr. Erin E. Jones M.S. (Age 52)
    Executive VP & COO
    Comp: $689.87k
  • Dr. Karin Jooss Ph.D. (Age 59)
    Executive VP and Head of Research & Development
    Comp: $748.2k
  • Ms. Vassiliki Economides (Age 44)
    Executive VP & CFO
  • Mr. James Cho
    Chief Accounting Officer
  • Mr. George E. MacDougall
    Director of Investor Relations & Corporate Communications
  • Ms. Stacy Proctor
    Executive VP & Chief People Officer
  • Dr. Matthew J. Hawryluk M.B.A. (Age 46)
    Ph.D., Executive VP & Chief Business Officer

GRTS Stock Analysis - Frequently Asked Questions

Should I buy or sell Gritstone bio stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gritstone bio in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GRTS shares.
View GRTS analyst ratings
or view top-rated stocks.

What is Gritstone bio's stock price target for 2024?

4 brokerages have issued twelve-month price objectives for Gritstone bio's stock. Their GRTS share price targets range from $3.00 to $7.00. On average, they anticipate the company's stock price to reach $4.75 in the next twelve months. This suggests a possible upside of 493.8% from the stock's current price.
View analysts price targets for GRTS
or view top-rated stocks among Wall Street analysts.

How have GRTS shares performed in 2024?

Gritstone bio's stock was trading at $2.04 at the beginning of the year. Since then, GRTS shares have decreased by 60.8% and is now trading at $0.80.
View the best growth stocks for 2024 here
.

Are investors shorting Gritstone bio?

Gritstone bio saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 12,690,000 shares, a decrease of 16.0% from the April 30th total of 15,110,000 shares. Based on an average daily trading volume, of 2,980,000 shares, the days-to-cover ratio is currently 4.3 days. Approximately 12.8% of the shares of the stock are short sold.
View Gritstone bio's Short Interest
.

When is Gritstone bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our GRTS earnings forecast
.

How were Gritstone bio's earnings last quarter?

Gritstone bio, Inc. (NASDAQ:GRTS) issued its earnings results on Thursday, May, 9th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.04. The company earned $1.74 million during the quarter, compared to analyst estimates of $5.90 million. Gritstone bio had a negative net margin of 926.13% and a negative trailing twelve-month return on equity of 232.42%. During the same period last year, the firm earned ($0.30) EPS.

What ETF holds Gritstone bio's stock?

Morningstar US Small Growth holds 23,628 shares of GRTS stock, representing 2.17% of its portfolio.

What is Andrew Allen's approval rating as Gritstone bio's CEO?

1 employees have rated Gritstone bio Chief Executive Officer Andrew Allen on Glassdoor.com. Andrew Allen has an approval rating of 100% among the company's employees. This puts Andrew Allen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Gritstone bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Novan (NOVN), Sorrento Therapeutics (SRNE), Zosano Pharma (ZSAN), Enerplus (ERF), Oncolytics Biotech (ONCY), SCYNEXIS (SCYX) and CBL & Associates Properties (CBL).

When did Gritstone bio IPO?

Gritstone bio (GRTS) raised $85 million in an IPO on Friday, September 28th 2018. The company issued 6,100,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays acted as the underwriters for the IPO and BTIG was co-manager.

Who are Gritstone bio's major shareholders?

Gritstone bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Redmile Group LLC (5.30%), Vanguard Group Inc. (4.42%), Affinity Asset Advisors LLC (0.00%), Artal Group S.A. (0.95%), Susquehanna Fundamental Investments LLC (0.23%) and BNP Paribas Financial Markets (0.05%). Insiders that own company stock include Andrew R Allen, Erin Jones, Matthew Hawryluk and Vassiliki Economides.
View institutional ownership trends
.

How do I buy shares of Gritstone bio?

Shares of GRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GRTS) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners